Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy

Introduction and objective:  Patient perception of overactive bladder (OAB) treatment outcomes can be a useful indicator of benefit and may help drive persistence on treatment, which is known to be poor in OAB. It remains unclear whether OAB patients dissatisfied with one antimuscarinic can achieve satisfaction with another and supporting data are limited. This study investigated patient‐reported outcomes and clinical parameters during darifenacin treatment in OAB patients who expressed dissatisfaction with prior extended‐release (ER) oxybutynin or tolterodine therapy (administered for ≥ 1 week within the past year).

• Publication year

  2008

• Venue

  International journal of clinical practice

• Publication date

  2008-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1742-1241.2008.01893.xPMID 18811599PMCID 2680263
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Persistence, Adherence, and Switch Rates Among Extended-Release and Immediate-Release Overactive Bladder Medications in a Regional Managed Care Plan

  2008cited by this paper
• Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study

  2007cited by this paper
• Darifenacin treatment of patients ≥ 65 years with overactive bladder: results of a randomized, controlled, 12-week trial

  2007cited by this paper
• Health and Quality of Life Outcomes

  2006cited by this paper
• Patient-reported outcomes in overactive bladder: the influence of perception of condition and expectation for treatment benefit.

  2006cited by this paper
• Long‐term treatment with darifenacin for overactive bladder: results of a 2‐year, open‐label extension study

  2006cited by this paper
• Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).

  2006cited by this paper
• Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance

  2006cited by this paper
• The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder.

  2006cited by this paper
• Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment.

  2006cited by this paper
• MP-04.12: Solifenacin reduces overactive bladder symptoms and improves health-related quality of life in patients previously receiving tolterodine

  2006cited by this paper
• An investigation of dose titration with darifenacin, an M3‐selective receptor antagonist

  2005cited by this paper
• Functional Selectivity of Muscarinic Receptor Antagonists for Inhibition of M3-Mediated Phosphoinositide Responses in Guinea Pig Urinary Bladder and Submandibular Salivary Gland

  2004cited by this paper

• Deciphering Therapeutic Targeting of Cathepsin B Using Repurposed Drug Darifenacin

  2025cites this paper
• Darifenacin: a promising chitinase 3-like 1 inhibitor to tackle drug resistance in pancreatic ductal adenocarcinoma

  2024cites this paper
• Associations between the Patient Perception of Bladder Condition score and overactive bladder syndrome symptoms at baseline and upon treatment

  2022cites this paper
• Comparison of efficacy of mirabegron and darifenacin in overactive bladder- a prospective study

  2020influential citation
• A comprehensive SARS-CoV-2 genomic analysis identifies potential targets for drug repurposing

  2020cites this paper
• Management of Overactive Bladder in the Young Man

  2019cites this paper
• Sacral Neuromodulation for Overactive Bladder

  2018cites this paper
• Therapeutic benefit in patients switching tolterodine to other novel antimuscarinic agents 157 PALABRAS CLAVE

  2017cites this paper
• Is There a Relationship Between Patient-Reported Satisfaction and Persistence on Overactive Bladder Syndrome Pharmacotherapy?

  2017cites this paper
• Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY)

  2017cites this paper
• Medical and Surgical Treatment for Overactive Bladder

  2017cites this paper
• Treatment Patterns for Patients on Overactive Bladder Therapy: A Retrospective Statistical Analysis Using Canadian Claims Data

  2016cites this paper
• A prospective, comparative study of the occurrence and severity of constipation with darifenacin and trospium in overactive bladder.

  2015influential citation
• The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial

  2015cites this paper
• The effect of mirabegron on patient-related outcomes in patients with overactive bladder: the results of post hoc correlation and responder analyses using pooled data from three randomized Phase III trials

  2015cites this paper
• Therapeutic benefit in patients switching tolterodine to other novel antimuscarinic agents.

  2014cites this paper
• Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER

  2014cites this paper
• Defining response and non-response to treatment in patients with overactive bladder: a systematic review

  2014cites this paper
• Therapeutic benefit in patients switching tolterodine to other novel antimuscarinic agents

  2014cites this paper
• Randomized controlled trial of cyclic and continuous therapy with trospium and solifenacin combination for severe overactive bladder in elderly patients with regard to patient compliance

  2014cites this paper
• Severity of overactive bladder symptoms and response to dose escalation in a randomized, double‐blind trial of solifenacin (SUNRISE)

  2013cites this paper
• Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies

  2013cites this paper
• Do Effects on Bowel Patterns Imposed by Solifenacin Always Have Negative Impacts on Treating Patients with Overactive Bladder (OAB)?

  2013cites this paper
• Results of a randomized phase III trial of mirabegron in patients with overactive bladder.

  2013cites this paper
• Urinary Incontinence: Diagnosis and Treatment in the Elderly

  2013cites this paper
• Management of urinary incontinence.

  2012cites this paper
• Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline.

  2012cites this paper
• Summary of Anticholinergic Pharmacotherapy Available for Overactive Bladder Dysfunction

  2012cites this paper
• Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective study

  2012cites this paper
• A review and additional post-hoc analyses of the incidence and impact of constipation observed in darifenacin clinical trials

  2012influential citation
• Overactive Bladder: Pathophysiology, Diagnostics, and Therapies

  2012cites this paper
• Benefits and Harms of Pharmacologic Treatment for Urinary Incontinence in Women

  2012cites this paper
• Clinical Use of Tolterodine Extended Release in Overactive Bladder

  2012cites this paper
• Diagnosis and treatment of overactive bladder.

  2011cites this paper
• The medical treatment of overactive bladder, including current and future treatments

  2011cites this paper
• Patient satisfaction with the benefits of overactive bladder treatment: Exploration of influencing factors and development of a satisfaction assessment instrument

  2011cites this paper
• Evaluación de los motivos del cambio de tratamiento para la vejiga hiperactiva

  2011cites this paper
• An Overview of the Clinical Use of Antimuscarinics in the Treatment of Overactive Bladder

  2011cites this paper
• [Assessment of reasons for overactive bladder treatment change].

  2011cites this paper
• Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature

  2011cites this paper
• Assessment of reasons for overactive bladder treatment change

  2011cites this paper
• Modeling dose-response relationships of the effects of fesoterodine in patients with overactive bladder

  2010cites this paper
• Anticholinergics for urge incontinence

  2010cites this paper
• Overactive Bladder: Diagnosis and Treatment

  2010cites this paper
• Detrusor overactivity: an overview

  2010influential citation
• Current and future approaches to the management of female urinary incontinence.

  2009cites this paper
• Defining efficacy in the treatment of overactive bladder syndrome.

  2009cites this paper
• Complex pelvic floor failure and associated problems.

  2009cites this paper
• Behavioral Intervention versus Pharmacotherapy or Their Combinations in the Management of Overactive Bladder Dysfunction

  2009cites this paper
• Efficacy of Darifenacin in Patients with Varying Baseline Symptom Severity

  2009cites this paper
• Overactive bladder medication switch studies – Vive le différence?

  2008cites this paper